Stock Track | Capricor Therapeutics Plunges 8.68% After-Hours Following Massive Intraday Rally on Positive Trial Results

Stock Track12-04

Capricor Therapeutics (CAPR) saw its shares drop 8.68% in after-hours trading on Wednesday, following a dramatic intraday surge fueled by positive Phase 3 trial results for its Duchenne muscular dystrophy (DMD) treatment, Deramiocel.

The stock had skyrocketed earlier in the day, with gains of up to 399%, after the company announced that its HOPE-3 study met both primary and secondary endpoints, demonstrating significant skeletal and cardiac benefits for patients. The results were seen as a potential breakthrough for the rare disease treatment.

The after-hours decline is likely due to profit-taking by investors who capitalized on the day's substantial gains, a common occurrence following such sharp rallies. The stock's volatility was also evident through multiple trading halts during the session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1122904936?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-04 05:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122904936","market":"us","top_or_hot":-1,"title":"Stock Track | Capricor Therapeutics Plunges 8.68% After-Hours Following Massive Intraday Rally on Positive Trial Results","media":"Stock Track","content":"<p>Capricor Therapeutics (CAPR) saw its shares drop 8.68% in after-hours trading on Wednesday, following a dramatic intraday surge fueled by positive Phase 3 trial results for its Duchenne muscular dystrophy (DMD) treatment, Deramiocel.</p><p>The stock had skyrocketed earlier in the day, with gains of up to 399%, after the company announced that its HOPE-3 study met both primary and secondary endpoints, demonstrating significant skeletal and cardiac benefits for patients. The results were seen as a potential breakthrough for the rare disease treatment.</p><p>The after-hours decline is likely due to profit-taking by investors who capitalized on the day's substantial gains, a common occurrence following such sharp rallies. The stock's volatility was also evident through multiple trading halts during the session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Capricor Therapeutics Plunges 8.68% After-Hours Following Massive Intraday Rally on Positive Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Capricor Therapeutics Plunges 8.68% After-Hours Following Massive Intraday Rally on Positive Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-12-04 05:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Capricor Therapeutics (CAPR) saw its shares drop 8.68% in after-hours trading on Wednesday, following a dramatic intraday surge fueled by positive Phase 3 trial results for its Duchenne muscular dystrophy (DMD) treatment, Deramiocel.</p><p>The stock had skyrocketed earlier in the day, with gains of up to 399%, after the company announced that its HOPE-3 study met both primary and secondary endpoints, demonstrating significant skeletal and cardiac benefits for patients. The results were seen as a potential breakthrough for the rare disease treatment.</p><p>The after-hours decline is likely due to profit-taking by investors who capitalized on the day's substantial gains, a common occurrence following such sharp rallies. The stock's volatility was also evident through multiple trading halts during the session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CAPR","symbol_name":"Capricor Therapeutics Inc","start_time":0,"source_url":"","article_id":"1122904936","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122904936","pubTimestamp":1764797537,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Capricor Therapeutics (CAPR) saw its shares drop 8.68% in after-hours trading on Wednesday, following a dramatic intraday surge fueled by positive Phase 3 trial results for its Duchenne muscular...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CAPR":"Capricor Therapeutics Inc"},"translate_title":"个股追踪|Capricor Therapeutics盘后暴跌8.68%，此前因试验结果积极而盘中大幅上涨","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAPR":1},"content_text":"Capricor Therapeutics (CAPR) saw its shares drop 8.68% in after-hours trading on Wednesday, following a dramatic intraday surge fueled by positive Phase 3 trial results for its Duchenne muscular dystrophy (DMD) treatment, Deramiocel.The stock had skyrocketed earlier in the day, with gains of up to 399%, after the company announced that its HOPE-3 study met both primary and secondary endpoints, demonstrating significant skeletal and cardiac benefits for patients. The results were seen as a potential breakthrough for the rare disease treatment.The after-hours decline is likely due to profit-taking by investors who capitalized on the day's substantial gains, a common occurrence following such sharp rallies. The stock's volatility was also evident through multiple trading halts during the session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1122904936","isCrawlerRequest":true}